Nyxoah earnings date
Nyxoah (5YI) Q3 2026 Earnings Report
DE:5YI Q3 2026 EPS Results
- Actual EPS
- -EUR 0.18
- Consensus EPS
- -EUR 0.31
- Beat/Miss
- Beat by +EUR 0.13
- One Year Ago EPS
- -EUR 0.63
DE:5YI Q3 2026 Revenue Results
- Actual Revenue
- EUR 9.17M
- Expected Revenue
- EUR 9.71M
- Beat/Miss
- Missed by -EUR 538.00K
- YoY Revenue Growth
- +365.01%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Nyxoah's next earnings date is estimated for March 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, supported by 365% year-over-year global revenue growth, accelerating U.S. sequential growth, expanding surgeon and account adoption, international growth, improved gross margin, positive clinical results, and progress toward a potential CCC indication expansion. The main negative factors were the reduction in full-year 2026 revenue guidance, the sequential decline in cash and financial assets, the continuing operating loss, and the need to manage the commercial ramp. Highlights significantly outweighed lowlights.
For the full year 2026, Nyxoah expects global net revenue in the range of EUR 33 million-EUR 35 million and gross margin in the range of 60%-62%; the updated revenue guidance is based on U.S. revenues that are more reflective of historical ramps for a new technology, as physicians and centers build experience with Genio. The company’s priorities are to deliver against its updated 2026 revenue guidance, drive utilization in existing U.S. accounts while training new doctors and expanding into new accounts, advance the CCC label expansion opportunity through FDA review of its PMA supplement, and maintain financial discipline while investing behind its highest return and highest growth opportunities.
- Strong Third-Quarter Revenue GrowthGlobal net revenue was EUR 9.2 million, up 365% year over year and 19% sequentially. U.S. net revenue was EUR 6.7 million, representing 29% sequential growth, accelerating from 22% growth in the second quarter.
- Positive U.S. Commercial Launch MomentumManagement described the U.S. launch as showing robust performance for a new product, with an annualized Q3 revenue run rate of almost EUR 27 million or $31 million, which management characterized as best in class.
- Expansion of U.S. Surgeon and Account BaseThe company trained 80 new surgeons in the third quarter, bringing the total to 342 trained surgeons. It activated 53 new accounts, bringing the total to 233 active Genio accounts, and had 447 patients actively undergoing prior authorization entering the fourth quarter.
- Focused Commercial InfrastructureNyxoah had 55 sales representatives and 233 active accounts at the end of the third quarter. Management plans to continue training new doctors and activating new accounts while focusing on deeper utilization within existing accounts.
- International Revenue GrowthInternational revenue was EUR 2.5 million, up 42% compared with the third quarter of 2025. Management said the international business continues to perform in line with expectations and that the company continues to execute in focused markets with a disciplined approach.
- Gross Margin ExpansionThird-quarter gross margin was 63.1%, compared with 60.5% in the third quarter of 2025, an improvement of 260 basis points year over year. Management said the improvement was driven by spreading cost of goods sold over a higher volume of devices.
- Reduced Operating LossTotal operating loss was EUR 21.9 million in the third quarter, compared with EUR 24.4 million in the third quarter of 2025.
- Progress Toward Lower Cash BurnManagement said it remains committed to disciplined spending and reducing cash burn quarter over quarter. In the Q&A, management stated that cash burn was reduced by EUR 2.5 million.
- Broad and Stable Reimbursement CoverageCMS and commercial payer coverage remained broad and stable, while the market access team continued executing on prior authorization submissions.
- Higher 2027 Facility ReimbursementCMS's final 2027 reimbursement rule increased hospital outpatient reimbursement under C-code C8011 from EUR 31,526 to EUR 35,072, approximately 11%, and ambulatory surgical center reimbursement from EUR 27,563 to EUR 31,283, approximately 13%. Management said these facility increases strengthen the economic value of the Genio procedure.
- Positive ACCCESS Clinical ResultsThe ACCCESS U.S. pivotal study met its core primary efficacy and safety endpoints in patients with complete concentric collapse. At 12 months, the Apnea-Hypopnea Index responder rate was 77.2% and the ODI responder rate was 87.7%, both highly statistically significant, with zero device- and procedure-related serious adverse events.
- Potential CCC Indication ExpansionNyxoah submitted a PMA supplement to the FDA to expand Genio's U.S. indication to include complete concentric collapse patients. Management stated that CCC patients account for about one in four patients evaluated for this therapy and currently have no hypoglossal nerve stimulation option in the United States.
- Differentiated Bilateral TherapyManagement stated that Genio is the only bilateral hypoglossal nerve stimulation therapy on the market and described it as meaningfully differentiated from the competition. The company said bilateral stimulation could provide an alternative for physicians and patients and potentially address CCC patients if the PMA supplement is approved.
- Long-Term Real-World Evidence ProgramNyxoah initiated the U.S. BREATHE post-approval study to build long-term real-world evidence for bilateral hypoglossal nerve stimulation in routine clinical practice.
- Transition Toward a Commercially Centric OrganizationManagement's short- to medium-term objectives include refocusing Nyxoah from an R&D and clinical development organization to a commercially centric organization, continuing to invest in U.S. market penetration while maintaining international growth, and expanding gross margins while managing operating expenses prudently.
- Continued Investment in Growth OpportunitiesManagement plans to continue investing in commercial infrastructure, train additional doctors, recruit more sales representatives, expand into new accounts, and invest behind the company's highest-return and highest-growth opportunities.
DE:5YI Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 25, 2027 | 2026 (Q4) | -0.17- | -0.59 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.31-0.18 | -0.63 | 71.90% (+0.45) | |
| Aug 05, 2026 | 2026 (Q2) | -0.39-0.58 | -0.55 | -4.90% (-0.03) | |
| May 12, 2026 | 2026 (Q1) | -0.50-0.37 | -0.6 | 38.29% (+0.23) | |
| Mar 19, 2026 | 2025 (Q4) | -0.54-0.59 | -0.46 | -26.57% (-0.12) | |
| Nov 13, 2025 | 2025 (Q3) | -0.59-0.63 | -0.5 | -27.02% (-0.13) | |
| Aug 18, 2025 | 2025 (Q2) | -0.57-0.55 | -0.43 | -28.74% (-0.12) | |
| May 14, 2025 | 2025 (Q1) | -0.47-0.60 | -0.41 | -44.10% (-0.18) | |
| Mar 13, 2025 | 2024 (Q4) | -0.47-0.46 | -0.38 | -22.16% (-0.08) | |
| Nov 06, 2024 | 2024 (Q3) | -0.45-0.50 | -0.27 | -86.47% (-0.23) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
